Role of the Breast Cancer Resistance Protein (BCRP/ABCG2) in Drug Transport—an Update

The human breast cancer resistance protein (BCRP, gene symbol ABCG2) is an ATP-binding cassette (ABC) efflux transporter. It was so named because it was initially cloned from a multidrug-resistant breast cancer cell line where it was found to confer resistance to chemotherapeutic agents such as mitoxantrone and topotecan. Since its discovery in 1998, the substrates of BCRP have been rapidly expanding to include not only therapeutic agents but also physiological substances such as estrone-3-sulfate, 17β-estradiol 17-(β-d-glucuronide) and uric acid. Likewise, at least hundreds of BCRP inhibitors have been identified. Among normal human tissues, BCRP is highly expressed on the apical membranes of the placental syncytiotrophoblasts, the intestinal epithelium, the liver hepatocytes, the endothelial cells of brain microvessels, and the renal proximal tubular cells, contributing to the absorption, distribution, and elimination of drugs and endogenous compounds as well as tissue protection against xenobiotic exposure. As a result, BCRP has now been recognized by the FDA to be one of the key drug transporters involved in clinically relevant drug disposition. We published a highly-accessed review article on BCRP in 2005, and much progress has been made since then. In this review, we provide an update of current knowledge on basic biochemistry and pharmacological functions of BCRP as well as its relevance to drug resistance and drug disposition.

[1]  E. Shin,et al.  Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan‐pharmacokinetics and clinical outcome in patients with advanced non‐small cell lung cancer , 2007, Cancer.

[2]  T. Ishikawa,et al.  Novel camptothecin analogues that circumvent ABCG2‐associated drug resistance in human tumor cells , 2004, International journal of cancer.

[3]  H. McLeod,et al.  ABCG2 Pharmacogenetics , 2004, Clinical Cancer Research.

[4]  S. Zeng,et al.  Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms. , 2013, Die Pharmazie.

[5]  W. T. Beck,et al.  Identification of a Novel Estrogen Response Element in the Breast Cancer Resistance Protein (ABCG2) Gene , 2004, Cancer Research.

[6]  Joseph W. Polli,et al.  An Unexpected Synergist Role of P-Glycoprotein and Breast Cancer Resistance Protein on the Central Nervous System Penetration of the Tyrosine Kinase Inhibitor Lapatinib (N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016) , 2009, Drug Metabolism and Disposition.

[7]  G. Kéri,et al.  High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. , 2004, Molecular pharmacology.

[8]  L. Doyle,et al.  Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene. , 2001, Biochimica et biophysica acta.

[9]  C. Rioufol,et al.  Suspicion of Drug-Drug Interaction between High-Dose Methotrexate and Proton Pump Inhibitors: A Case Report – Should the Practice Be Changed? , 2011, Chemotherapy.

[10]  M. J. van de Vijver,et al.  Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. , 2001, Cancer research.

[11]  J. Unadkat,et al.  Breast Cancer Resistance Protein 1 Limits Fetal Distribution of Nitrofurantoin in the Pregnant Mouse , 2007, Drug Metabolism and Disposition.

[12]  K. Maeda,et al.  SLCO1B1 (OATP1B1, an Uptake Transporter) and ABCG2 (BCRP, an Efflux Transporter) Variant Alleles and Pharmacokinetics of Pitavastatin in Healthy Volunteers , 2007, Clinical pharmacology and therapeutics.

[13]  S. Ambudkar,et al.  Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1. , 2013, Biochemical pharmacology.

[14]  X. Chu,et al.  In Vitro Assessment of Drug-Drug Interaction Potential of Boceprevir Associated with Drug Metabolizing Enzymes and Transporters , 2013, Drug Metabolism and Disposition.

[15]  D. Briggs,et al.  Dimerization of ABCG2 Analysed by Bimolecular Fluorescence Complementation , 2011, PloS one.

[16]  C. Hirayama,et al.  Association of Genetic Polymorphisms in the Influx Transporter SLCO1B3 and the Efflux Transporter ABCB1 With Imatinib Pharmacokinetics in Patients With Chronic Myeloid Leukemia , 2011, Therapeutic drug monitoring.

[17]  S. Brennecke,et al.  The ABC transporter BCRP/ABCG2 is a placental survival factor, and its expression is reduced in idiopathic human fetal growth restriction , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  David S. Miller,et al.  17-β-Estradiol: A Powerful Modulator of Blood–Brain Barrier BCRP Activity , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[19]  Y. Miao,et al.  hsa-miR-520h downregulates ABCG2 in pancreatic cancer cells to inhibit migration, invasion, and side populations , 2010, British Journal of Cancer.

[20]  A. di Pietro,et al.  Dexamethasone down-regulates ABCG2 expression levels in breast cancer cells. , 2008, Biochemical and biophysical research communications.

[21]  J. Allen,et al.  Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines. , 2001, Bioorganic & medicinal chemistry letters.

[22]  Eszter Hazai,et al.  Predicting P-Glycoprotein-Mediated Drug Transport Based On Support Vector Machine and Three-Dimensional Crystal Structure of P-glycoprotein , 2011, PloS one.

[23]  Ya-li Liu,et al.  Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[24]  T. Litman,et al.  A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2). , 2001, Biochimica et biophysica acta.

[25]  H. Nakauchi,et al.  The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype , 2001, Nature Medicine.

[26]  H. Tagawa,et al.  Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia , 2010, Journal of Human Genetics.

[27]  Honggang Wang,et al.  Membrane topology of the human breast cancer resistance protein (BCRP/ABCG2) determined by epitope insertion and immunofluorescence. , 2008, Biochemistry.

[28]  J. Cheng,et al.  Breast cancer resistance protein expression and 5-fluorouracil resistance. , 2008, Biomedical and environmental sciences : BES.

[29]  Christin Müller,et al.  Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar. , 2009, Journal of medicinal chemistry.

[30]  W. Dalton,et al.  Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line. , 1999, Cancer research.

[31]  T. Litman,et al.  Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  S H Kaufmann,et al.  The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. , 2001, Cancer research.

[33]  L. Doyle,et al.  Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. , 2000, Cancer research.

[34]  M. Barrand,et al.  Localisation of breast cancer resistance protein in microvessel endothelium of human brain , 2002, Neuroreport.

[35]  P. Ney,et al.  Increased expression of the Abcg2 transporter during erythroid maturation plays a role in decreasing cellular protoporphyrin IX levels. , 2005, Blood.

[36]  Ruoping Tang,et al.  MRP3, BCRP, and P-Glycoprotein Activities are Prognostic Factors in Adult Acute Myeloid Leukemia , 2005, Clinical Cancer Research.

[37]  Honggang Wang,et al.  The Breast Cancer Resistance Protein (Bcrp1/Abcg2) Limits Fetal Distribution of Glyburide in the Pregnant Mouse: An Obstetric-Fetal Pharmacology Research Unit Network and University of Washington Specialized Center of Research Study , 2007, Molecular Pharmacology.

[38]  Jing Li,et al.  Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients , 2007, Cancer biology & therapy.

[39]  Hui Peng,et al.  Dynamic vs Static ABCG2 Inhibitors to Sensitize Drug Resistant Cancer Cells , 2010, PloS one.

[40]  L. Pendyala,et al.  VX-710 (Biricodar) Increases Drug Retention and Enhances Chemosensitivity in Resistant Cells Overexpressing P-Glycoprotein, Multidrug Resistance Protein, and Breast Cancer Resistance Protein , 2004, Clinical Cancer Research.

[41]  Yi Zhang,et al.  HIV Protease Inhibitors Are Inhibitors but Not Substrates of the Human Breast Cancer Resistance Protein (BCRP/ABCG2) , 2004, Journal of Pharmacology and Experimental Therapeutics.

[42]  T. Litman,et al.  Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. , 1999, Cancer letters.

[43]  Michael Wiese,et al.  Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2). , 2008, Bioorganic & medicinal chemistry.

[44]  C. Hrycyna,et al.  The nature of amino acid 482 of human ABCG2 affects substrate transport and ATP hydrolysis but not substrate binding , 2006, Protein science : a publication of the Protein Society.

[45]  J. Unadkat,et al.  FUNCTIONAL ANALYSIS OF THE HUMAN VARIANTS OF BREAST CANCER RESISTANCE PROTEIN: I206L, N590Y, AND D620N , 2005, Drug Metabolism and Disposition.

[46]  T. Litman,et al.  Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. , 2001, Cancer research.

[47]  Z. Ni,et al.  Identification of proline residues in or near the transmembrane helices of the human breast cancer resistance protein (BCRP/ABCG2) that are important for transport activity and substrate specificity. , 2011, Biochemistry.

[48]  Xin Wang,et al.  Induction of cellular resistance to nucleoside reverse transcriptase inhibitors by the wild-type breast cancer resistance protein. , 2004, Biochemical pharmacology.

[49]  K. Iseki,et al.  Expression Level of ABCG2 in the Placenta Decreases from the Mid Stage to the End of Gestation , 2005, Bioscience, biotechnology, and biochemistry.

[50]  H. Guchelaar,et al.  Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib , 2010, Investigational New Drugs.

[51]  S. Nishimura,et al.  ABCG2 confers resistance to indolocarbazole compounds by ATP-dependent transport. , 2002, Biochemical and biophysical research communications.

[52]  D. Ross,et al.  Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. , 2012, Biochemical pharmacology.

[53]  T. Tsuruo,et al.  Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists. , 2003, Molecular cancer therapeutics.

[54]  S. Rabindran,et al.  Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. , 1998, Cancer research.

[55]  J. Schuetz,et al.  The Stem Cell Marker Bcrp/ABCG2 Enhances Hypoxic Cell Survival through Interactions with Heme* , 2004, Journal of Biological Chemistry.

[56]  S. Cho,et al.  Impact of ABCC2, ABCG2 and SLCO1B1 polymorphisms on the pharmacokinetics of pitavastatin in humans. , 2013, Drug metabolism and pharmacokinetics.

[57]  Yi Wang,et al.  Involvement of Multiple Transporters in the Hepatobiliary Transport of Rosuvastatin , 2008, Drug Metabolism and Disposition.

[58]  T. Tsuruo,et al.  Dominant‐negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S‐S dependent homodimerization , 2002, International journal of cancer.

[59]  K. Noguchi,et al.  Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics , 2014, Pharmacogenomics and personalized medicine.

[60]  T. Ishikawa,et al.  A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of arginine-482 in methotrexate transport. , 2003, The Biochemical journal.

[61]  W. Haefeli,et al.  Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. , 2006, The Journal of antimicrobial chemotherapy.

[62]  H. Rosing,et al.  The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[63]  H. W. Lee,et al.  Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[64]  R. Callaghan,et al.  Purification and 3D structural analysis of oligomeric human multidrug transporter ABCG2. , 2006, Structure.

[65]  C. Flexner,et al.  Differential Effects of Tipranavir plus Ritonavir on Atorvastatin or Rosuvastatin Pharmacokinetics in Healthy Volunteers , 2009, Antimicrobial Agents and Chemotherapy.

[66]  L. Lue,et al.  ABCG2 Is Upregulated in Alzheimer's Brain with Cerebral Amyloid Angiopathy and May Act as a Gatekeeper at the Blood–Brain Barrier for Aβ1–40 Peptides , 2009, The Journal of Neuroscience.

[67]  R. Ford,et al.  The human breast cancer resistance protein (BCRP/ABCG2) shows conformational changes with mitoxantrone. , 2010, Structure.

[68]  R. Mehvar,et al.  Effects of Atazanavir/Ritonavir or Fosamprenavir/Ritonavir on the Pharmacokinetics of Rosuvastatin , 2008, Journal of cardiovascular pharmacology.

[69]  Xiaokun Cai,et al.  Fluorescence resonance energy transfer (FRET) analysis demonstrates dimer/oligomer formation of the human breast cancer resistance protein (BCRP/ABCG2) in intact cells. , 2010, International journal of biochemistry and molecular biology.

[70]  Shuzhong Zhang,et al.  Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein. , 2005, Biochemical pharmacology.

[71]  M. Niemi,et al.  Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.

[72]  J. Verweij,et al.  Effect of ABCG2 genotype on the oral vioavailability of topotecan , 2005, Cancer biology & therapy.

[73]  Yi Zhang,et al.  BCRP Transports Dipyridamole and is Inhibited by Calcium Channel Blockers , 2005, Pharmaceutical Research.

[74]  H. Rosing,et al.  Multidrug Transporter ABCG2/Breast Cancer Resistance Protein Secretes Riboflavin (Vitamin B2) into Milk , 2006, Molecular and Cellular Biology.

[75]  E. L. Volk,et al.  Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. , 2003, Cancer research.

[76]  G. Szakács,et al.  Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti‐cancer effects and pharmacological properties , 2009, British journal of pharmacology.

[77]  S. Bates,et al.  Characterization of Oligomeric Human Half-ABC Transporter ATP-binding Cassette G2* , 2004, Journal of Biological Chemistry.

[78]  R. Callaghan,et al.  Multiple drugbinding sites on the R482G isoform of the ABCG2 transporter , 2006, British journal of pharmacology.

[79]  Reinhart A. F. Reithmeier,et al.  Mapping the Ends of Transmembrane Segments in a Polytopic Membrane Protein , 1997, The Journal of Biological Chemistry.

[80]  T. Litman,et al.  Effect of Walker A mutation (K86M) on oligomerization and surface targeting of the multidrug resistance transporter ABCG2 , 2005, Journal of Cell Science.

[81]  P. Carrupt,et al.  QSAR analysis and molecular modeling of ABCG2-specific inhibitors. , 2009, Advanced drug delivery reviews.

[82]  P. Leung,et al.  Progesterone Receptor (PR) Isoforms PRA and PRB Differentially Regulate Expression of the Breast Cancer Resistance Protein in Human Placental Choriocarcinoma BeWo Cells , 2008, Molecular Pharmacology.

[83]  Y. Nishiwaki,et al.  Breast Cancer Resistance Protein Impacts Clinical Outcome in Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer , 2004, Clinical Cancer Research.

[84]  Yuichi Sugiyama,et al.  Pharmacogenetic Characterization of Sulfasalazine Disposition Based on NAT2 and ABCG2 (BCRP) Gene Polymorphisms in Humans , 2008, Clinical pharmacology and therapeutics.

[85]  Weiwei Li,et al.  Harmful effect of ERβ on BCRP‐mediated drug resistance and cell proliferation in ERα/PR‐negative breast cancer , 2013, The FEBS journal.

[86]  T. Litman,et al.  Regulation of ABCG2 Expression at the 3′ Untranslated Region of Its mRNA through Modulation of Transcript Stability and Protein Translation by a Putative MicroRNA in the S1 Colon Cancer Cell Line , 2008, Molecular and Cellular Biology.

[87]  Paul D. Martin,et al.  Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine , 2004, Clinical pharmacology and therapeutics.

[88]  J. Polli,et al.  Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design , 2013, Xenobiotica; the fate of foreign compounds in biological systems.

[89]  J. Schellens,et al.  Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  E. Hudson,et al.  The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). , 2000, Journal of cell science.

[91]  Yvonne S. Lin,et al.  Interindividual variability in the hepatic expression of the human breast cancer resistance protein (BCRP/ABCG2): effect of age, sex, and genotype. , 2013, Journal of pharmaceutical sciences.

[92]  K. Maeda,et al.  The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers , 2011, Pharmacogenetics and genomics.

[93]  Yan Shu,et al.  Polymorphism of ORM1 Is Associated with the Pharmacokinetics of Telmisartan , 2013, PloS one.

[94]  J. Schellens,et al.  Mechanism of the Pharmacokinetic Interaction between Methotrexate and Benzimidazoles , 2004, Cancer Research.

[95]  B. Sarkadi,et al.  Characterization of Drug Transport, ATP Hydrolysis, and Nucleotide Trapping by the Human ABCG2 Multidrug Transporter , 2002, The Journal of Biological Chemistry.

[96]  S. Grimm,et al.  ATP-DEPENDENT TRANSPORT OF ROSUVASTATIN IN MEMBRANE VESICLES EXPRESSING BREAST CANCER RESISTANCE PROTEIN , 2006, Drug Metabolism and Disposition.

[97]  Xiaokun Cai,et al.  Transmembrane helices 1 and 6 of the human breast cancer resistance protein (BCRP/ABCG2): identification of polar residues important for drug transport. , 2010, American journal of physiology. Cell physiology.

[98]  Masahiko Watanabe,et al.  ATP-Binding Cassette Transporter G2 Mediates the Efflux of Phototoxins on the Luminal Membrane of Retinal Capillary Endothelial Cells , 2006, Pharmaceutical Research.

[99]  S. Bates,et al.  Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity , 2003, British Journal of Cancer.

[100]  P. Neuvonen,et al.  Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. , 2009, Pharmacogenomics.

[101]  S. Bates,et al.  Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. , 2003, Cancer research.

[102]  E. Lee,et al.  Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers. , 2011, British journal of clinical pharmacology.

[103]  M. Gasparetto,et al.  Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies , 2007, Leukemia.

[104]  S. Zeng,et al.  ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics. , 2013, Die Pharmazie.

[105]  A. S. Gross,et al.  The ABCG2 C421A polymorphism does not affect oral nitrofurantoin pharmacokinetics in healthy Chinese male subjects. , 2008, British journal of clinical pharmacology.

[106]  P. Neuvonen,et al.  ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin , 2009, Clinical pharmacology and therapeutics.

[107]  S. Zeng,et al.  CYP2C9*3(1075A>C), MDR1 G2677T/A and MDR1 C3435T are Determinants of Inter-subject Variability in Fluvastatin Pharmacokinetics in Healthy Chinese Volunteers , 2012, Arzneimittelforschung/Drug Research.

[108]  Y. Sawada,et al.  Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. , 2009, British journal of clinical pharmacology.

[109]  J. Shim,et al.  The effect of ABCG2 V12M, Q141K and Q126X, known functional variants in vitro, on the disposition of lamivudine. , 2007, British journal of clinical pharmacology.

[110]  A. Biri,et al.  Role of Oxidative Stress in Intrauterine Growth Restriction , 2007, Gynecologic and Obstetric Investigation.

[111]  E. Tan,et al.  The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients , 2011, Cancer Chemotherapy and Pharmacology.

[112]  J. Nortier,et al.  Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors , 2009, Investigational New Drugs.

[113]  G. Kéri,et al.  Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). , 2005, Cancer research.

[114]  E. Boerwinkle,et al.  Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout , 2009, Proceedings of the National Academy of Sciences.

[115]  D. Richardson,et al.  Molecular Pharmacology of ABCG2 and Its Role in Chemoresistance , 2013, Molecular Pharmacology.

[116]  K. Maeda,et al.  Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP , 2012, British journal of pharmacology.

[117]  T. Ishikawa,et al.  Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. , 2001, Biochemical and biophysical research communications.

[118]  Y. Sugimoto,et al.  Role of Cys‐603 in dimer/oligomer formation of the breast cancer resistance protein BCRP/ABCG2 , 2005, Cancer science.

[119]  Marilyn E Morris,et al.  MicroRNA-328 Negatively Regulates the Expression of Breast Cancer Resistance Protein (BCRP/ABCG2) in Human Cancer Cells , 2009, Molecular Pharmacology.

[120]  S. Bates,et al.  Upregulation of ABCG2 by Romidepsin via the Aryl Hydrocarbon Receptor Pathway , 2011, Molecular Cancer Research.

[121]  O. Ogawa,et al.  Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacokinetics. , 2012, Drug metabolism and pharmacokinetics.

[122]  Kazuya Maeda,et al.  Physiologically Based Pharmacokinetic Modeling to Predict Transporter-Mediated Clearance and Distribution of Pravastatin in Humans , 2009, Journal of Pharmacology and Experimental Therapeutics.

[123]  J. Unadkat,et al.  The Breast Cancer Resistance Protein (Bcrp1/Abcg2) Limits Fetal Distribution of Glyburide in the Pregnant Mouse – An OPRU Network and UW SCOR Study , 2007 .

[124]  J. Schellens,et al.  Absence of N-linked glycosylation does not affect plasma membrane localization of breast cancer resistance protein (BCRP/ABCG2) , 2005, Cancer Chemotherapy and Pharmacology.

[125]  A. Schinkel,et al.  Physiological and pharmacological roles of ABCG2 (BCRP): recent findings in Abcg2 knockout mice. , 2009, Advanced drug delivery reviews.

[126]  A. S. Gross,et al.  Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration. , 2010, Journal of pharmaceutical sciences.

[127]  Mariël Brok,et al.  Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. , 2004, Blood.

[128]  Sagar Agarwal,et al.  The Role of the Breast Cancer Resistance Protein (ABCG2) in the Distribution of Sorafenib to the Brain , 2011, Journal of Pharmacology and Experimental Therapeutics.

[129]  S. Bates,et al.  Comparison of ATP-Binding Cassette Transporter Interactions with the Tyrosine Kinase Inhibitors Imatinib, Nilotinib, and Dasatinib , 2010, Drug Metabolism and Disposition.

[130]  Alfred H. Schinkel,et al.  Human Breast Cancer Resistance Protein: Interactions with Steroid Drugs, Hormones, the Dietary Carcinogen 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and Transport of Cimetidine , 2005, Journal of Pharmacology and Experimental Therapeutics.

[131]  M. Kuo,et al.  Novobiocin sensitizes BCRP/MXR/ABCP overexpressing topotecan-resistant human breast carcinoma cells to topotecan and mitoxantrone. , 2003, Anticancer research.

[132]  S. Bates,et al.  Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. , 2007, Cancer research.

[133]  Qingcheng Mao,et al.  Structure and function of the human breast cancer resistance protein (BCRP/ABCG2). , 2010, Current drug metabolism.

[134]  Jérôme Guitton,et al.  Substituted chromones as highly potent nontoxic inhibitors, specific for the breast cancer resistance protein. , 2012, Journal of medicinal chemistry.

[135]  S. Cho,et al.  Influence of ABCC2, SLCO1B1, and ABCG2 Polymorphisms on the Pharmacokinetics of Olmesartan , 2012, Journal of cardiovascular pharmacology.

[136]  F H Hausheer,et al.  Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[137]  F. Russel,et al.  The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane. , 2008, Kidney international.

[138]  Y. Sugimoto,et al.  Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2. , 2005, Cancer research.

[139]  Li Li,et al.  pH-Dependent Transport of Pemetrexed by Breast Cancer Resistance Protein , 2011, Drug Metabolism and Disposition.

[140]  Young Hak Kim,et al.  Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. , 2009, Lung cancer.

[141]  R. Bendayan,et al.  Expression of ATP-Binding Cassette Membrane Transporters in Rodent and Human Sertoli Cells: Relevance to the Permeability of Antiretroviral Therapy at the Blood-Testis Barrier , 2012, Journal of Pharmacology and Experimental Therapeutics.

[142]  M. Morris,et al.  Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. , 2004, Molecular pharmacology.

[143]  Thomas A. Hopf,et al.  Protein structure prediction from sequence variation , 2012, Nature Biotechnology.

[144]  Y. Wang,et al.  Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells , 2007, Leukemia.

[145]  U. Christians,et al.  Multidrug Resistance-Associated Protein 2 (MRP2/ABCC2) Haplotypes Significantly Affect the Pharmacokinetics of Tacrolimus in Kidney Transplant Recipients , 2013, Clinical Pharmacokinetics.

[146]  島野 宏一.  Hepatic oval cells have the side population phenotype defined by expression of ATP-binding cassette transporter ABCG2/BCRP1 , 2005 .

[147]  H. Puy,et al.  Null alleles of ABCG2 encoding the breast cancer resistance protein define the new blood group system Junior , 2012, Nature Genetics.

[148]  Zsolt Bikádi,et al.  Predicting substrates of the human breast cancer resistance protein using a support vector machine method , 2013, BMC Bioinformatics.

[149]  E. Barta,et al.  Peroxisome Proliferator-activated Receptor γ-regulated ABCG2 Expression Confers Cytoprotection to Human Dendritic Cells* , 2006, Journal of Biological Chemistry.

[150]  Ji-Young Park,et al.  Effect of ABCG2 genotypes on the pharmacokinetics of A771726, an active metabolite of prodrug leflunomide, and association of A771726 exposure with serum uric acid level , 2011, European Journal of Clinical Pharmacology.

[151]  H. McLeod,et al.  ABCG2 Pharmacogenetics: Ethnic Differences in Allele Frequency and Assessment of Influence on Irinotecan Disposition , 2004 .

[152]  R. Robey,et al.  Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. , 2008, Cancer research.

[153]  J. Gerber,et al.  Drug/Drug Interaction Between Lopinavir/Ritonavir and Rosuvastatin in Healthy Volunteers , 2008, Journal of acquired immune deficiency syndromes.

[154]  S. Bates,et al.  Aberrant Promoter Methylation of the ABCG2 Gene in Renal Carcinoma , 2006, Molecular and Cellular Biology.

[155]  A. Herrmann,et al.  Reversal of breast cancer resistance protein–mediated drug resistance by tryprostatin A , 2003, International journal of cancer.

[156]  Z. Ni,et al.  ATP-binding cassette efflux transporters in human placenta. , 2011, Current pharmaceutical biotechnology.

[157]  H. McLeod,et al.  Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes , 2006, Investigational New Drugs.

[158]  Yi Zhang,et al.  Regulation of BCRP/ABCG2 expression by progesterone and 17beta-estradiol in human placental BeWo cells. , 2006, American journal of physiology. Endocrinology and metabolism.

[159]  B. Dijkmans,et al.  Development of sulfasalazine resistance in human T cells induces expression of the multidrug resistance transporter ABCG2 (BCRP) and augmented production of TNFα , 2004, Annals of the rheumatic diseases.

[160]  J. Frasor,et al.  Proinflammatory Cytokines Enhance Estrogen-dependent Expression of the Multidrug Transporter Gene ABCG2 through Estrogen Receptor and NFκB Cooperativity at Adjacent Response Elements*♦ , 2010, The Journal of Biological Chemistry.

[161]  T. Lai,et al.  Association of Genetic Polymorphisms in the Influx Transporter SLCO1B3 and the Efflux Transporter ABCB1 With Imatinib Pharmacokinetics in Patients With Chronic Myeloid Leukemia , 2011, Retina.

[162]  Yukio Kato,et al.  Interaction of Novel Platelet-Increasing Agent Eltrombopag with Rosuvastatin via Breast Cancer Resistance Protein in Humans , 2014, Drug Metabolism and Disposition.

[163]  S. Bates,et al.  Mutational analysis of threonine 402 adjacent to the GXXXG dimerization motif in transmembrane segment 1 of ABCG2. , 2010, Biochemistry.

[164]  Jashvant D Unadkat,et al.  Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP). , 2007, Journal of pharmaceutical sciences.

[165]  Y. Miki,et al.  C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. , 2002, Molecular cancer therapeutics.

[166]  Liwu Fu,et al.  Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2 (Cancer Research (2008) 68, (7905-7914)) , 2008 .

[167]  T. Dale,et al.  The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk , 2005, Nature Medicine.

[168]  Sharon Marsh,et al.  Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype , 2004, Clinical pharmacology and therapeutics.

[169]  Biochemical interaction of anti-HCV telaprevir with the ABC transporters P-glycoprotein and breast cancer resistance protein , 2013, BMC Research Notes.

[170]  B. Tomlinson,et al.  Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients. , 2013, Pharmacogenomics.

[171]  B. Sarkadi,et al.  Effects of putative catalytic base mutation E211Q on ABCG2-mediated methotrexate transport. , 2009, Biochemistry.

[172]  M. Schell,et al.  ABCG2 expression, function, and promoter methylation in human multiple myeloma. , 2006, Blood.

[173]  Yoo-Seok Yoon,et al.  Breast cancer resistance protein expression is associated with early recurrence and decreased survival in resectable pancreatic cancer patients , 2012, Pathology international.

[174]  B. Goh,et al.  Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan‐induced neutropenia in Asian cancer patients , 2007, Cancer science.

[175]  J. Foekens,et al.  RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[176]  Qingcheng Mao,et al.  Role of the breast cancer resistance protein (ABCG2) in drug transport , 2005, The AAPS Journal.

[177]  T Ishikawa,et al.  Quantitative structure-activity relationship (QSAR) analysis to predict drug-drug interactions of ABC transporter ABCG2. , 2012, Mini reviews in medicinal chemistry.

[178]  Marilyn E. Morris,et al.  Structure–Activity Relationships and Quantitative Structure–Activity Relationships for Breast Cancer Resistance Protein (ABCG2) , 2009, The AAPS Journal.

[179]  Honggang Wang,et al.  Role of Basic Residues within or near the Predicted Transmembrane Helix 2 of the Human Breast Cancer Resistance Protein in Drug Transport , 2010, Journal of Pharmacology and Experimental Therapeutics.

[180]  P. Houghton,et al.  Imatinib Mesylate Is a Potent Inhibitor of the ABCG2 (BCRP) Transporter and Reverses Resistance to Topotecan and SN-38 in Vitro , 2004, Cancer Research.

[181]  Y. Sugimoto,et al.  Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants , 2003, International journal of cancer.

[182]  Peter W Swaan,et al.  Identification of novel breast cancer resistance protein (BCRP) inhibitors by virtual screening. , 2013, Molecular pharmaceutics.

[183]  塩澤 健.  Reversal of breast cancer resistance protein (BCRP/ABCG2) -mediated drug resistance by novobiocin, a coumermycin antibiotic , 2004 .

[184]  Thomas Ried,et al.  Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2 , 2009, Molecular Cancer Therapeutics.

[185]  H. Kusuhara,et al.  Kinetic Analysis of the Cooperation of P-Glycoprotein (P-gp/Abcb1) and Breast Cancer Resistance Protein (Bcrp/Abcg2) in Limiting the Brain and Testis Penetration of Erlotinib, Flavopiridol, and Mitoxantrone , 2010, Journal of Pharmacology and Experimental Therapeutics.

[186]  Zhiyong Guo,et al.  The 44-kDa Pim-1 Kinase Phosphorylates BCRP/ABCG2 and Thereby Promotes Its Multimerization and Drug-resistant Activity in Human Prostate Cancer Cells* , 2008, Journal of Biological Chemistry.

[187]  I. Catalá,et al.  Frequent expression of the multi‐drug resistance‐associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP‐21 monoclonal antibody in paraffin‐embedded material , 2002, The Journal of pathology.

[188]  M. Hirata,et al.  Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia , 2014, Medical Oncology.

[189]  C. Rudin,et al.  Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[190]  Hui Zhang,et al.  Progesterone Negatively Regulates BCRP in Progesterone Receptor-Positive Human Breast Cancer Cells , 2013, Cellular Physiology and Biochemistry.

[191]  Xin Wang,et al.  Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. , 2003, Molecular pharmacology.

[192]  N. Shaik,et al.  Substrate-Dependent Breast Cancer Resistance Protein (Bcrp1/Abcg2)-Mediated Interactions: Consideration of Multiple Binding Sites in in Vitro Assay Design , 2009, Drug Metabolism and Disposition.

[193]  Suneet Shukla,et al.  The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2. , 2006, Biochemistry.

[194]  Joe Palandra,et al.  Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe , 2008, Pharmacogenetics and genomics.

[195]  S. Bates,et al.  ABCG2-mediated transport of photosensitizers: Potential impact on photodynamic therapy , 2005, Cancer biology & therapy.

[196]  A. V. van Herwaarden,et al.  The Breast Cancer Resistance Protein (BCRP/ABCG2) Affects Pharmacokinetics, Hepatobiliary Excretion, and Milk Secretion of the Antibiotic Nitrofurantoin , 2005, Molecular Pharmacology.

[197]  A. Nolan,et al.  Nestin-positive progenitor cells derived from adult human pancreatic islets of Langerhans contain side population (SP) cells defined by expression of the ABCG2 (BCRP1) ATP-binding cassette transporter. , 2002, Biochemical and biophysical research communications.

[198]  N. Maragakis,et al.  Selective increase of two ABC drug efflux transporters at the blood–spinal cord barrier suggests induced pharmacoresistance in ALS , 2012, Neurobiology of Disease.

[199]  C. Landen,et al.  Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer. , 2005, Cancer research.

[200]  E. Jaworska,et al.  Side population/ABCG2-positive cells represent a heterogeneous group of haemopoietic cells: implications for the use of adult stem cells in transplantation and plasticity protocols , 2005, Bone Marrow Transplantation.

[201]  Fei Li,et al.  Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. , 2002, Cancer research.